Oncimmune Ltd of Nottingham at MEDICA 2018 in Düsseldorf -- COMPAMED Trade Fair

Oncimmune Ltd

Clinical Sciences Building, City Hospital, Hucknall Road, NG5 1PB Nottingham
United Kingdom of Great Britain and Northern Ireland

This company is co-exhibitor of
Gambica Association Limited

Hall map

MEDICA 2018 hall map (Hall 3A): stand 3AC07-2

Fairground map

MEDICA 2018 fairground map: Hall 3A

Our range of products

Product categories

  • 03  Diagnostics
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.03  Diagnostic tests for cancer

Diagnostic tests for cancer

Our products

Product category: Diagnostic tests for cancer

EarlyCDT®-Lung

EarlyCDT-Lung: a simple blood test for the early detection of lung cancer

  • Our clinically validated blood test for lung cancer measures a panel of 7 autoantibodies associated with small cell and non-small cell lung cancers at all stages of disease
  • EarlyCDT-Lung can detect lung cancer up to 4 years earlier than other methods. Test performance has been optimised for ‘rule-in’ use in conjunction with CT scanning
  • EarlyCDT-Lung can be used to assess the malignancy risk of CT-detected pulmonary nodules as a ‘rule-in’ test for lung cancer
  • It can also be used in conjunction with CT scanning to ‘rule-in’ and assess the risk of lung cancer in asymptomatic patients at increased risk of the disease. It is not a ‘rule-out’ test.
  • EarlyCDT-Lung can be billed in the US to most major payors. It is currently self-pay elsewhere in the world
  • The test requires a small blood sample either drawn by a phlebotomist or by the patient using a simple finger stick self-draw kit 
  • EarlyCDT-Lung test is run in our CLIA-certified laboratory in the US
  • It can be run in hospital laboratories outside the US using our proprietary CE and ISO 13845:2012 marked kit

More Less

Product category: Diagnostic tests for cancer

EarlyCDT®-Liver

EarlyCDT®-Liver is a simple blood test to aid detection and confirmation of HCC (hepatocellular carcinoma), in association with imaging, in high-risk patients with liver lesions of all sizes

  • EarlyCDT-Liver is complementary to imaging for the diagnosis of HCC. The very high specificity of the test makes it a clinically useful “confirmation” test
  • EarlyCDT-Liver detects HCC at all stages¹, with similar performance across all stages
  • It’s high specificity for early stage HCC (BCLC 0-B) can accelerate treatment and deliver improved patient outcomes
  • The test complements all imaging modalities, providing confirmatory data
For nodules assessed by ultrasound alone, a High positive EarlyCDT-Liver test result increases the risk of HCC by three to six times dependent on initial risk.

Make EarlyCDT-Liver part of your workup of liver nodule malignancy risk assessment, and to detect cancers in surveillance more quickly.

Results are reported as High, Moderate or No Significant Level of Biomarkers detected. Only High and Moderate results are clinically actionable. The test rules-in, and does not rule-out, for HCC in liver lesions.

¹ Macdonald I et al. Development and Validation of an ELISA test detecting a panel of Autoantibodies in combination with AFP for Early Detection of Hepatocellular Carcinoma.

More Less

About us

Company details

Oncimmune is a leading early cancer detection company

  • Our patented autoantibody assay technology can detect autoantibodies produced in response to cancer up to 4 years before symptomatic presentation of the disease
  • Oncimmune’s early cancer detection technology can be applied to many solid tumor cancer types
  • Our simple blood test for lung cancer, EarlyCDT®-Lung, is available now through physicians and is reimbursable in the US. In the UK and other regions, it is available self-pay. Over 155,000 commercial tests have been sold.
  • EarlyCDT-Lung can aid in the risk assessment of lung nodules and early detection of lung cancer in high-risk patients.
  • Oncimmune will launch a test for liver cancer in early 2018. We are developing tests for ovarian and breast cancers.
  • Oncimmune Ltd is headquartered in Nottingham, UK. Testing is conducted in our CLIA-approved laboratory, based in De Soto, Kansas, USA. We also offer test kits for use in professional laboratories outside the US.

More Less